WO2004007442A1 - プロスタグランジン誘導体 - Google Patents
プロスタグランジン誘導体 Download PDFInfo
- Publication number
- WO2004007442A1 WO2004007442A1 PCT/JP2003/008864 JP0308864W WO2004007442A1 WO 2004007442 A1 WO2004007442 A1 WO 2004007442A1 JP 0308864 W JP0308864 W JP 0308864W WO 2004007442 A1 WO2004007442 A1 WO 2004007442A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- formula
- pharmaceutically acceptable
- compound
- acceptable salt
- Prior art date
Links
- 150000003180 prostaglandins Chemical class 0.000 title claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 8
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims abstract description 5
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 claims abstract description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 5
- 125000005843 halogen group Chemical group 0.000 claims abstract description 4
- 239000001257 hydrogen Substances 0.000 claims abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000001309 chloro group Chemical class Cl* 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical class [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- -1 ethylene, vinylene Chemical group 0.000 abstract description 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 50
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 37
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 101000692460 Bos taurus Prostaglandin F synthase 1 Proteins 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 229910002091 carbon monoxide Inorganic materials 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- HCUOEKSZWPGJIM-YBRHCDHNSA-N (e,2e)-2-hydroxyimino-6-methoxy-4-methyl-5-nitrohex-3-enamide Chemical compound COCC([N+]([O-])=O)\C(C)=C\C(=N/O)\C(N)=O HCUOEKSZWPGJIM-YBRHCDHNSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- BCBDIPGKPAERPG-UHFFFAOYSA-N but-3-yne-1-thiol Chemical group SCCC#C BCBDIPGKPAERPG-UHFFFAOYSA-N 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000003682 fluorination reaction Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- FGOJCPKOOGIRPA-UHFFFAOYSA-N 1-o-tert-butyl 4-o-ethyl 5-oxoazepane-1,4-dicarboxylate Chemical compound CCOC(=O)C1CCN(C(=O)OC(C)(C)C)CCC1=O FGOJCPKOOGIRPA-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 210000003703 cisterna magna Anatomy 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006622 cycloheptylmethyl group Chemical group 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- WCRDXYSYPCEIAK-UHFFFAOYSA-N dibutylstannane Chemical compound CCCC[SnH2]CCCC WCRDXYSYPCEIAK-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Substances CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- ZKCZXVODRKOWIY-UHFFFAOYSA-N diphenylstannane Chemical compound C=1C=CC=CC=1[SnH2]C1=CC=CC=C1 ZKCZXVODRKOWIY-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000012155 injection solvent Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 108010021666 lipase II Proteins 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000003328 mesylation reaction Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- BHLUERUPCAAQGF-UHFFFAOYSA-N prop-2-yne-1-thiol Chemical compound SCC#C BHLUERUPCAAQGF-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003163 prostaglandin D2 derivatives Chemical class 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- HQSDNUBPNJEFFQ-CQSZACIVSA-N tert-butyl-[(1s)-1-cyclohexylprop-2-ynoxy]-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[C@H](C#C)C1CCCCC1 HQSDNUBPNJEFFQ-CQSZACIVSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000007070 tosylation reaction Methods 0.000 description 1
- NFHRNKANAAGQOH-UHFFFAOYSA-N triphenylstannane Chemical compound C1=CC=CC=C1[SnH](C=1C=CC=CC=1)C1=CC=CC=C1 NFHRNKANAAGQOH-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a novel prostaglandin derivative, a pharmaceutically acceptable salt thereof, or a sleep inducer containing the hydrate thereof as an active ingredient.
- PGD 2 is to be a humoral factor that regulates the expression and maintenance of sleep in the brain are already known, sleep induced by PGD 2 in monkeys, natural sleep spontaneous on EEG and behavioral Natl. Acad. Sci. USA, Vol. 85, pp. 4082-4086, 1988, and was expected as a compound having a new sleep-inducing effect.
- PGD 2 derivatives including PGD 2 have not been put into practical use due to problems such as the ability to enter the brain and stability.
- WO 99/61419 discloses a compound having an ethynylene group in the ⁇ chain, but this compound is difficult to crystallize, and has a problem in formulation. Disclosure of the invention
- An object of the present invention is to provide a PG derivative having an excellent sleep-inducing effect.
- the present invention provides a compound represented by the formula (I):
- Y represents an ethylene group, a vinylene group or Echiniren group
- R ' is C 3 _
- the present invention provides a compound of the formula (I), wherein R 1 is C 3 _ ,. Or a pharmaceutically acceptable salt or hydrate thereof, wherein the prostaglandin derivative is a cycloalkyl group or a C 4 , 3 cycloalkylalkyl group.
- a prostaglandin derivative as described above wherein in formula (I), X is a chlorine atom or a bromine atom substituted with ⁇ or i3, a pharmaceutically acceptable salt thereof. It is a salt or a hydrate thereof.
- the present invention provides the prostaglandin derivative as described above, wherein in formula (I), Y is an ethynylene group, a pharmaceutically acceptable salt thereof or a hydrate thereof. .
- the present invention provides a compound of the formula (I) wherein R 2 is a C ⁇ 2 R 3 group.
- R 2 is a C ⁇ 2 R 3 group.
- a pharmaceutical composition comprising the prostaglandin derivative described above, a pharmaceutically acceptable salt thereof or a hydrate thereof.
- the halogen atom includes a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
- cycloalkyl group C 3 1 Q for example, cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, heptyl group cycloalkyl, etc. Shikurookuchiru group.
- Cycloalkyl - C it is _ 3 alkyl group. Examples thereof include a cyclopropylmethyl group, a cyclobutylmethyl group, a cyclopentylmethyl group, a cyclopentylethyl group, a cyclohexylmethyl group, a cyclohexylethyl group, a cycloheptylmethyl group, and the like.
- Examples of the C 1-4 linear or branched alkyl group include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group and a tert-butyl group. And the like.
- the linear or branched alkenyl group of c 2 _ 4 includes, for example, an aryl group, a crotyl group, a 2-methyl-2-propyl group and the like.
- Pharmaceutically acceptable salts include, for example, salts with alkali metals such as sodium and potassium, salts with alkaline earth metals such as calcium and magnesium, ammonium, methylamine, dimethylamine, cyclopentylamine, benzyla Salts with min, piperidine, monoethanolamine, diethanolamine, monomethylmonoethanolamine, tromethamine, lysine, tris (hydroxymethyl) aminomethane and the like can be mentioned.
- n an integer of 1 to 4, and preferably 1 or 2 from the viewpoint of crystallinity.
- Compounds of formula (I) can be prepared, for example, by the methods summarized in the following reaction schemes.
- TB S represents a tert _ heptyl dimethylsilyl group
- R 31 represents a C, _ 4 alkyl or C 2 _ 4 alkenyl group
- pi is Represents 1 or 2
- Z represents a halogen atom
- X, Y, R 1 and n are as defined above.
- a compound of the formula (II ⁇ ) is used, and at 78 to 0 ° C, Y is ethynylene.
- the compound of formula (III) is used to obtain a compound of the group, and the reaction is carried out at 0 to 30.
- the compound of formula (VI) is obtained by reacting in an organic solvent (for example, benzene, toluene, xylene, n-hexane, n-pentane, acetone, etc.) at 780 to 100 ° C. .
- organic solvent for example, benzene, toluene, xylene, n-hexane, n-pentane, acetone, etc.
- bases eg, organic amines such as triethylamine, diisopropylamine, pyridine, and dimethylaniline
- polyvinylpyrrolidone diisopropylaminomethyl-polystyrene
- Base resin such as polystyrene
- organic solvent eg, benzene, toluene, xylene, n-hexane, n-pentane, acetone, etc.
- the compound of the formula (VI) can also be obtained by reacting at 00 ° C.
- the compound of the formula (VII) (or the formula (VII ′)) can be treated with, for example, 1 to 6 equivalents of methanesulfonyl chloride or p_toluenesulfonyl chloride in a suitable solvent such as pyridine, if necessary.
- a suitable solvent such as pyridine
- mesylation or tosylation with _20 to 40 ⁇ is followed by chlorination with 1 to 16 equivalents of tetra_n-butylammonium chloride to formula (VIII) (or formula (VIII) VIII ')))
- X is a chlorine atom.
- bromination and fluorination can also be performed by a usual method.
- bromination can be obtained by reacting 1 to 10 equivalents of carbon tetrabromide in acetonitrile in the presence of 1 to 10 equivalents of triphenylphosphine and 1 to 10 equivalents of pyridine. Fluorination is obtained, for example, by reacting 5 to 20 equivalents of getylaminosulfur-trifluoride (DAST) in methylene chloride.
- DAST getylaminosulfur-trifluoride
- a compound of formula (VIII) (or formula (VII ⁇ )) in a suitable inert organic solvent (eg, tetrahydrofuran, getyl ether, etc.) in a base (eg, alkyllithium such as n-butyllithium) )
- a suitable inert organic solvent eg, tetrahydrofuran, getyl ether, etc.
- a base eg, alkyllithium such as n-butyllithium
- the compound of the formula (XI) (or the formula (XI ′)) can be obtained by reacting carbon dioxide gas instead of the formula (IX).
- the compound of formula (Xa) (or formula (Xa ′)) is treated with hydrofluoric acid, pyridinium poly (hydrogen fluoride), hydrochloric acid, etc. under the conditions usually used.
- the tert-butyldimethylsilyl group which is a protecting group for a hydroxyl group, is removed from a mixture of ethanol, ethanol, acetonitrile, or a mixed solvent thereof, or a mixed solvent thereof with water, and the compound of formula (Ia) (or formula ( la '))) can be obtained.
- the compound of the formula (Ia) (or the formula (la ') is added to a buffer such as a phosphate buffer or a Tris-HCl buffer, and if necessary, an organic solvent (acetone, methanol, ethanol).
- a buffer such as a phosphate buffer or a Tris-HCl buffer
- an organic solvent acetone, methanol, ethanol.
- the PG derivative and the formula (lb) (or the formula (lb ')) according to the present invention can be obtained by hydrolysis by reacting with an enzyme using a water-miscible substance such as, for example.
- Examples include enzymes produced by microorganisms (for example, enzymes produced by microorganisms belonging to the genus Candida and Pseudomonas), enzymes produced from animal organs (for example, enzymes prepared from pig liver and bush tongue)
- Specific examples of commercially available enzymes include lipase VII (manufactured by Sigma and derived from Candida microorganism), lipase AY (manufactured by Amano Pharmaceutical and derived from Candida microorganism), and rivase PS ( Amano Pharmaceutical , Lipase MF (manufactured by Amano Pharmaceuticals, derived from Pseudomonas sp.), PLE (manufactured from Sigma, pig liver), Lipase II (manufactured by Sigma, from bush kidney), Lipo Protein lipase (manufactured by Tokyo Kasei Kogyo Co., Ltd., prepared from Buta Teng).
- the amount of the enzyme to be used may be appropriately selected according to the titer of the enzyme and the amount of the substrate [compound of the formula (Ia) (or the compound of the formula Ia ')]. Double weight parts.
- the reaction temperature is 25-50 ° C, preferably 30-4 Ot :.
- the PG derivative according to the present invention by hydrolyzing the compound of the formula (Ia) (or the formula (la ′)) in a solvent usually used for hydrolysis using a base, the PG derivative according to the present invention, the formula (lb) (Or the formula (lb ')).
- the base used here include lithium hydroxide and potassium carbonate
- the solvent include acetonitrile, acetone, methanol, ethanol, water, and a mixed solvent thereof.
- Representative compounds of the formula (I) according to the present invention include the following. Compound XY n PR 1 R 2. 1 5th position *>
- the compounds of the present invention can be administered systemically or locally orally or intravenously, or parenterally, such as by nasal administration. These can be orally administered, for example, in the form of tablets, powders, granules, powders, capsules, solutions, emulsions, suspensions, etc., which can be produced by a conventional method.
- preparations for intravenous administration aqueous or non-aqueous solutions, emulsions, suspensions, solid preparations which are dissolved in an injection solvent immediately before use, and the like can be used.
- a solution or powder (hard capsule) containing a drug is generally sprayed quantitatively into the nasal cavity using a special nasal dropper or nebulizer.
- the compound of the present invention can also be formulated by forming an inclusion compound with, for example, or cyclodextrin or methylated cyclodextrin.
- the aqueous or non-aqueous solution, emulsion, suspension and the like can be administered by injection or the like. Dosage varies depending on age, weight, etc.
- the dose is 1 ng to 1 mg Z days for an adult, and is administered once or several times a day.
- Test example Steep induction test by intraocular administration
- Example 1 (2) 4-mercapto-1-butyne was replaced by 3-mercapto-1-propyne, and 2-decarboxyl-1-propyne was obtained in substantially the same manner as in Example 1 (2).
- 2,16,17,18,19,20 Hexanol—15—Cyclohexyl—3,3,4,4,13,14—Hexadehydro-6-thia_PGE 1
- Example 1 (2) 5-mercapto-1-pentine was used in place of 4-mercapto-1-butyne.
- 1a Decarpoxy—16,17,18,19,20—Pennyl nor 15—Cyclohexyl—1a, 1a, 2,2,13,14—Hexadehydro-6 —Thia— PGE 11 1,15-bis (tert-butyldimethylsilyl ether) was obtained.
- the compound according to the present invention Since the compound according to the present invention has a sufficient sleep-inducing effect, it is useful as a medicament for sleep induction.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2492260A CA2492260C (en) | 2002-07-12 | 2003-07-11 | Prostaglandin derivatives |
EP03741366A EP1553083B1 (en) | 2002-07-12 | 2003-07-11 | Prostaglandin derivatives |
JP2004521199A JP4351630B2 (ja) | 2002-07-12 | 2003-07-11 | プロスタグランジン誘導体 |
AT03741366T ATE440818T1 (de) | 2002-07-12 | 2003-07-11 | Prostaglandinderivate |
DE60329008T DE60329008D1 (de) | 2002-07-12 | 2003-07-11 | Prostaglandinderivate |
AU2003280977A AU2003280977B2 (en) | 2002-07-12 | 2003-07-11 | Prostaglandin derivatives |
US10/521,115 US7763652B2 (en) | 2002-07-12 | 2003-07-11 | Prostaglandin derivatives |
HK05110052A HK1078072A1 (en) | 2002-07-12 | 2005-11-10 | Prostaglandin derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-204908 | 2002-07-12 | ||
JP2002204908 | 2002-07-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004007442A1 true WO2004007442A1 (ja) | 2004-01-22 |
Family
ID=30112741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/008864 WO2004007442A1 (ja) | 2002-07-12 | 2003-07-11 | プロスタグランジン誘導体 |
Country Status (12)
Country | Link |
---|---|
US (1) | US7763652B2 (ja) |
EP (1) | EP1553083B1 (ja) |
JP (1) | JP4351630B2 (ja) |
CN (1) | CN1283624C (ja) |
AT (1) | ATE440818T1 (ja) |
AU (1) | AU2003280977B2 (ja) |
CA (1) | CA2492260C (ja) |
DE (1) | DE60329008D1 (ja) |
ES (1) | ES2331792T3 (ja) |
HK (1) | HK1078072A1 (ja) |
RU (1) | RU2311407C2 (ja) |
WO (1) | WO2004007442A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2474426C1 (ru) * | 2011-12-26 | 2013-02-10 | Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН | Простамиды и их аналоги, обладающие нейрозащитным действием |
EP3456710B1 (en) * | 2016-05-09 | 2021-06-30 | Agc Inc. | Novel prostaglandin derivative |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002161082A (ja) * | 2000-09-18 | 2002-06-04 | Taisho Pharmaceut Co Ltd | プロスタグランジン誘導体 |
EP1211242A1 (en) * | 1999-09-10 | 2002-06-05 | Taisho Pharmaceutical Co., Ltd | Prostaglandin derivatives |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999061419A1 (fr) | 1998-05-25 | 1999-12-02 | Taisho Pharmaceutical Co., Ltd. | Derive de prostaglandine |
JP2001151749A (ja) * | 1999-11-24 | 2001-06-05 | Taisho Pharmaceut Co Ltd | プロスタグランジン誘導体 |
PL373819A1 (en) * | 2002-08-09 | 2005-09-19 | Taisho Pharmaceutical Co,Ltd. | Antipruritic agent |
-
2003
- 2003-07-11 EP EP03741366A patent/EP1553083B1/en not_active Expired - Lifetime
- 2003-07-11 ES ES03741366T patent/ES2331792T3/es not_active Expired - Lifetime
- 2003-07-11 RU RU2005103634/04A patent/RU2311407C2/ru not_active IP Right Cessation
- 2003-07-11 DE DE60329008T patent/DE60329008D1/de not_active Expired - Lifetime
- 2003-07-11 US US10/521,115 patent/US7763652B2/en not_active Expired - Fee Related
- 2003-07-11 CN CNB038150999A patent/CN1283624C/zh not_active Expired - Fee Related
- 2003-07-11 CA CA2492260A patent/CA2492260C/en not_active Expired - Fee Related
- 2003-07-11 AT AT03741366T patent/ATE440818T1/de not_active IP Right Cessation
- 2003-07-11 WO PCT/JP2003/008864 patent/WO2004007442A1/ja active Application Filing
- 2003-07-11 JP JP2004521199A patent/JP4351630B2/ja not_active Expired - Fee Related
- 2003-07-11 AU AU2003280977A patent/AU2003280977B2/en not_active Ceased
-
2005
- 2005-11-10 HK HK05110052A patent/HK1078072A1/xx not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1211242A1 (en) * | 1999-09-10 | 2002-06-05 | Taisho Pharmaceutical Co., Ltd | Prostaglandin derivatives |
JP2002161082A (ja) * | 2000-09-18 | 2002-06-04 | Taisho Pharmaceut Co Ltd | プロスタグランジン誘導体 |
Also Published As
Publication number | Publication date |
---|---|
RU2311407C2 (ru) | 2007-11-27 |
CN1665782A (zh) | 2005-09-07 |
DE60329008D1 (de) | 2009-10-08 |
AU2003280977B2 (en) | 2008-10-23 |
AU2003280977A1 (en) | 2004-02-02 |
JP4351630B2 (ja) | 2009-10-28 |
ES2331792T3 (es) | 2010-01-15 |
EP1553083B1 (en) | 2009-08-26 |
JPWO2004007442A1 (ja) | 2005-11-10 |
EP1553083A4 (en) | 2006-04-12 |
HK1078072A1 (en) | 2006-03-03 |
EP1553083A1 (en) | 2005-07-13 |
CA2492260C (en) | 2010-12-07 |
CN1283624C (zh) | 2006-11-08 |
ATE440818T1 (de) | 2009-09-15 |
US20060094788A1 (en) | 2006-05-04 |
CA2492260A1 (en) | 2004-01-22 |
US7763652B2 (en) | 2010-07-27 |
RU2005103634A (ru) | 2005-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100526282B1 (ko) | 디플루오로프로스타글란딘유도체및그의용도 | |
JP4354644B2 (ja) | プロスタグランジン誘導体 | |
WO1995018101A1 (fr) | Derive de prostaglandine, son sel et utilisation de ce compose | |
WO2004007442A1 (ja) | プロスタグランジン誘導体 | |
EP0597095A1 (en) | Prostaglandin e1 analogue | |
ES2337981T3 (es) | Derivados de prostaglandina. | |
JP3506485B2 (ja) | プロスタグランジン誘導体 | |
JP2005194262A (ja) | プロスタグランジン誘導体を有効成分として含有する睡眠誘発剤 | |
JP2001122786A (ja) | 睡眠誘発剤 | |
WO2004074240A1 (ja) | プロスタグランジン誘導体 | |
EP0666257A1 (en) | Prostaglandin e 1? analog | |
JP2002155046A (ja) | プロスタグランジン誘導体 | |
JP3865843B2 (ja) | プロスタグランジンe1類縁体 | |
JP2001089443A (ja) | プロスタグランジン誘導体 | |
JP2001139544A (ja) | プロスタグランジン誘導体 | |
JP2001055375A (ja) | E型プロスタグランジン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004521199 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038150999 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003280977 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2492260 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2006094788 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10521115 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003741366 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2005103634 Country of ref document: RU Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2003741366 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10521115 Country of ref document: US |